Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Epstein-Barr virus latent membrane protein 1 (LMP1)
- Target
- LMP1
- Molecular classification
- Other (virus-encoded transmembrane protein), Oncoprotein, Membrane protein
01
Overview
Epstein-Barr virus latent membrane protein 1 (LMP1) is the major oncoprotein of EBV and a critical determinant of EBV-mediated transformation. LMP1 is a transmembrane integral protein with six membrane-spanning domains, a short N-terminal cytoplasmic tail, and a long C-terminal cytoplasmic segment containing three key activating regions (CTAR1, CTAR2, CTAR3). LMP1 functions as a constitutively active signaling molecule, mimicking CD40 receptor and activating NF-κB, JAK/STAT, and other downstream pathways. LMP1 induces changes in cellular survival, proliferation, immune responses, and apoptosis resistance, underlining its essential role in EBV-associated malignancies and latent infection. Its oligomerization and engagement of host adaptors facilitate complex signal transduction patterns, driving carcinogenesis and immune modulation. Despite being an attractive target for therapeutic intervention in EBV-associated cancers, direct drugs remain under development due to structural, biological, and safety considerations.
- Other names
- EBV latent membrane protein 1EBV LMP1Latent membrane protein 1
02
Mechanism of action
Inhibition of LMP1-induced signal transduction pathways (e.g., NF-κB, JAK/STAT) Blocking membrane oligomerization or function Disruption of LMP1-protein interactions (e.g., with TRAFs, IRF7)
03
Biological functions
Signal transductionCell cycle regulationApoptosis modulation (anti-apoptotic regulation)Upregulation of DNA methyltransferase activityInduction of cytokine productionImmune response modulationTransformation and survival of infected cellsDownregulation of cell adhesion moleculesRegulation of cell surface marker expression
04
Disease associations
Cancer (especially Hodgkin lymphoma, nasopharyngeal carcinoma, EBV-associated B cell and NK/T cell lymphoproliferative diseases)Infection (critical in EBV pathology and latency)Other (immune system modulation)
05
Safety considerations
Targeting LMP1 poses challenges due to its localization, membrane topology, and essential role in EBV survival and latency.Off-target effects may arise due to shared signaling pathways with human proteins (e.g., CD40, TNF receptor).Immune evasion by EBV-infected cells
06
Interacting drugs
No approved drugs directly targeting LMP1 currently; however, research is ongoing to develop therapies targeting LMP1, especially for EBV-associated cancers
1 more in the full profile.
07
Biomarkers
LMP1 protein expression (used for diagnosis and monitoring in EBV-associated cancers)EBV DNA load or latent viral gene expression
Beyond the preview
Go deeper on Epstein-Barr virus latent membrane protein 1 (LMP1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epstein-Barr virus latent membrane protein 1 (LMP1).